Cellectis S.A. (CLLS) is a French biotechnology company specializing in the development of immunotherapeutic drugs based on CRISPR/Cas9 cell editing technology. With a primary focus on developing therapies for cancer and genetic diseases, Cellectis is an innovative leader in the field of gene therapy. The company focuses on utilizing CRISPR/Cas9 cell editing technology to create therapeutic products that target cancer cells or correct genetic defects. Cellectis also collaborates with pharmaceutical companies on the development and commercialization of new therapeutic products. Cellectis S.A. (CLLS) shares could be suitable for investors seeking investment opportunities in biotechnology and innovative therapeutic therapies.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
